Sumitomo Dainippon Pharma Oncology

Sumitomo Pharma Oncology (formerly Sumitomo Dainippon Pharma Oncology) was a clinical-stage biopharmaceutical company dedicated to the development of novel cancer therapies. The company was established through the integration of Boston Biomedical and Tolero Pharmaceuticals, combining expertise in cancer stemness and small molecule kinase inhibition. Its pipeline focused on difficult-to-treat cancers, including acute myeloid leukemia, myelofibrosis, and solid tumors, with key assets such as dubermatinib and TP-3654. In July 2023, the company was merged with several other subsidiaries to form Sumitomo Pharma America, Inc. This consolidation aimed to streamline operations and accelerate the delivery of innovative medicines under the parent company, Sumitomo Pharma.